Back to the thread topic LOL.
So, I've tweaked some cash flow models and NPV analyses, and come up wth some interesting findings.
Constructed a model to replicate the PEA scenario/s, so I can adjust CapEx, OpEx, pricing etc and see what sort of impact these have on NPV for various other production and resource scenarios.
I've tested a couple of the PEA scenarios, and it delivers a very close result;
e.g. for the base case 15ktpa scenario at $15500/t, the PEA result was a pre-tax NPV of US$654M, the model shows US$638M.
It's not perfect but imo close enough for this purpose.
So, here's the summary...
Model accounts for:
- CapEx
- OpEx
- Sustaining capital
- Tax
- Royalties
- Admin costs
- Contingency
The pre-tax NPV outcome for a few scenarios are presented in the charts below.
Here are the scenarios illustrated, and their key features:
1/ 12ktpa for 14 years
- Assumes current resource size
- Ignores initial 2ktpa stage
- Assumed CapEx is US$200M plus $35M Contingency
2/ 12ktpa for 28 years
- Assumes resource size is doubled and can support this
- Ignores initial 2ktpa stage
- Assumed CapEx is US$200M plus $35M Contingency
3/ 22ktpa for 15 years
- Assumes resource size is doubled and can support this
- Ignores initial 2ktpa stage
- Assumed CapEx is US$400M plus $70M Contingency
For each scenario shown here, I increased the OpEx to $6k/t (from the low-$4k range in the PEA)
Royalties, sustaining capital etc were as per the PEA %s.
Shown below are pre-tax NPV outcomes using discount rates of 10% and 8%, for product pricing of $15.5k/t, $20k/t, $25k/t and $30k/t.
Pay attention to what happens if/as our resource is expanded and we (potentially) increase production beyond the 12ktpa! Wow.
10% discount rate:
8% discount rate:
I also ran a custom scenario with variable product pricing as follows:
12ktpa for 14 years (our current resource)
CapEx US$200M + US$35M Contingency
OpEx US$6k/t
Pricing:
Yr 1-3; US$50k/t
Yr 4-8; US$40k/t
Yr 9-14; US$30k/t
....At a DR of 8%, this delivers a pre-tax NPV of US$2.98B
Let that sink in.
Still double-checking the model for minor errors/issues, but so far seems ok.
Happy to run other scenarios suggested by genuine posters. Let me know.
Not advice
DYOR
DYOMaths
$$$$$$$$$$$$$$$$$$$AGY
Tick Tock
- Forums
- ASX - By Stock
- AGY
- AGY LOM Equivalent
AGY LOM Equivalent, page-61
-
- There are more pages in this discussion • 254 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AGY (ASX) to my watchlist
(20min delay)
|
|||||
Last
8.5¢ |
Change
-0.008(8.60%) |
Mkt cap ! $123.7M |
Open | High | Low | Value | Volume |
9.0¢ | 9.3¢ | 8.5¢ | $362.9K | 4.093M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
9 | 459867 | 8.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.7¢ | 93664 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
8 | 401162 | 0.085 |
4 | 219873 | 0.084 |
3 | 69062 | 0.083 |
3 | 336585 | 0.082 |
2 | 114691 | 0.081 |
Price($) | Vol. | No. |
---|---|---|
0.085 | 201 | 2 |
0.087 | 193664 | 2 |
0.088 | 232558 | 1 |
0.089 | 69615 | 2 |
0.090 | 91167 | 2 |
Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
Featured News
AGY (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online